Clinical Trial Update: Apatinib Versus Bevacizumab in Second-line Therapy for Colorectal Cancer(ABST-C) [Phase 2]

View source ↗

Summary

A phase 2 trial compares Apatinib to Bevacizumab as second-line therapy for colorectal cancer; the current status of the study is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Digestive System Cancer
• Gastrointestinal Cancer

Drugs mentioned

• Apatinib (apatinib)
• Bevacizumab (bevacizumab)

Snippet

Sponsor: Shenzhen People's Hospital | Conditions: Colorectal Neoplasms, Intestinal Neoplasms | Phase 2 | Status: UNKNOWN